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BACKGROUND: Osteosarcoma is the most prevalent primary malignant bone tumour in children and young adults, with poor survival in
40% of patients. To identify the signalling pathways involved in tumourigenesis, we compared gene expression in osteosarcoma with
that in its presumed normal counterparts.
METHODS: Genome-wide expression profiles were generated from 25 high-grade central osteosarcoma prechemotherapy biopsies,
5 osteoblastomas, 5 mesenchymal stem cell (MSC) populations and these same MSCs differentiated into osteoblasts. Genes that
were differentially expressed were analysed in the context of the pathways in which they function using the GenMAPP programme.
RESULTS: MSCs, osteoblasts, osteoblastomas and osteosarcomas clustered separately and thousands of differentially expressed genes
were identified. The most significantly altered pathways are involved in cell cycle regulation and DNA replication. Several upstream
components of the Wnt signalling pathway are downregulated in osteosarcoma. Two genes involved in degradation of b-catenin
protein, the key effectors of Wnt signalling, Axin and GSK3-b, show decreased expression, suggesting that Wnt signalling is no longer
under the control of regular signals. Comparing benign osteoblastomas with osteosarcomas identified cell cycle regulation as the most
prominently changed pathway.
CONCLUSION: These results show that upregulation of the cell cycle and downregulation of Wnt signalling have an important role in
osteosarcoma genesis. Gene expression differences between highly malignant osteosarcoma and benign osteoblastoma involve cell
cycle regulation.
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Osteosarcoma is the most common primary bone malignancy, with
a yearly incidence of approximately 6 per million children and 2
per million adults (Raymond et al, 2002). Peak incidence occurs in
late puberty, with 50% of patients being between 10 and 20 years of
age, and 60% younger than 25 years. Osteosarcoma in patients
over 40 years of age is, in a substantial number of cases, generally
considered secondary, such as after exposure to irradiation, or it
arises in areas of preexisting Paget’s disease of bone (Fuchs and
Pritchard, 2002). It might thus be considered as a different disease
than osteosarcoma in young patients.
Several histological subtypes are distinguished, of which
conventional high-grade central or intramedullary osteosarcoma
is the most common (75%) (Fletcher et al, 2002). The aetiology of
high-grade central osteosarcoma in young patients is elusive. No
benign or malignant precursor lesions are known. These tumours
recapitulate osteogenesis, compliant with their capacity to produce
osteoid, alkaline phosphatase, osteocalcin, osterix and bone
sialoprotein.
The outcome for patients with high-grade osteosarcoma has
improved substantially since the introduction of multimodal
chemotherapy, with present overall survival rates ranging from
65 to 75%. However, this improvement has reached a plateau
despite several trials opting for intensifying the dose or applying
alternative chemotherapy schedules. Increasing the dose of
chemotherapy before surgery only improved the response rate,
but not survival (George, 2007; Lewis et al, 2007b). To treat
patients who are refractory to chemotherapy or those who relapse,
alternative targets for therapy are required that can be identified
through knowledge of molecular biological characteristics of the
tumour.
Molecular studies on osteosarcoma are greatly hampered by
the enormous genetic instability that obscures the identification
of genetic loci involved in osteosarcoma genesis (Hogendoorn
et al, 2003), and furthermore by the lack of benign precursors and
no certainty of the normal counterpart or progenitor cells.
Osteoblastoma is a benign bone tumour occurring at the same
site, but this tumour has never been reported to progress to
osteosarcoma. A potential cell-of-origin of osteosarcomas is the
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smesenchymal stem cell (MSC), the precursor of osteoblasts
as has been suggested in mouse models (Tolar et al, 2007).
Genome-wide expression profiling to identify genes that are
involved in response to chemotherapy and survival of osteosarco-
ma has been reported (Ochi et al, 2004; Man et al, 2005; Mintz
et al, 2005). In all, 104, 44 and 60 differentially expressed genes
were reported when comparing good and poor responders to
chemotherapy. Remarkably, these lists of genes do not overlap by
one single gene.
Here we report on a genome-wide expression profiling study on
a homogeneous series of high-grade central osteosarcomas of
patients younger than 40 years of age. Using strict criteria to
correct for multiple testing, we were unable to identify genes that
were significantly different when comparing good and poor
responders. A comparison of osteosarcoma expression profiles
with the putative progenitor cells of osteosarcoma, that is, MSCs
and the same MSCs differentiated into osteoblasts, resulted in the
identification of large sets of genes that show very significant
differential expression. These genes could be grouped according to
signal transduction pathways in which they function, thereby
identifying possible culprit molecular events responsible for
osteosarcoma genesis.
MATERIALS AND METHODS
Patient material and mesenchymal stem cells
Patients and their clinical data are listed in Table 1. All patients
were treated at Leiden University Medical Center (LUMC). For
osteosarcoma patients, the difference in response to chemotherapy
was stratified as good or poor response, using the Huvos criteria
(Huvos, 1991). Good response was defined if o10% of tumour
cells are viable after pre-operative chemotherapy, poor response
if more than 10% of tumour cells are viable. This response rate
has been shown to be the best predictive marker for prognosis
(Bielack et al, 2002). Chemotherapy protocols include both pre-
and post-operative treatment and were comparable (Lewis et al,
2007a). Osteoblastoma patients were treated with surgery only.
The difference in survival of osteosarcoma was stratified as good if
patients were still alive after 5 years of follow-up, whereas poor
survivors were patients who died from their disease within this
time window. The disease course for osteoblastoma patients was
usually without remission, except for recurrence in one patient.
Ribonucleic acid was extracted from frozen biopsies that were
obtained before pre-operative chemotherapy was administered.
For osteosarcoma, core biopsies with at least 70% tumour cells and
Table 1 Clinical data
Sample ID Chip no. Type Age (years) Gender Subtype Adj. CT Chemo response Overall survival Metastasis
L1370 IB10 Osteosarcoma 14 Male HG Conv. PIA Good Good Lung
L1372 IB12 Osteosarcoma 10 Male HG Conv. AP Good Good 0
L1382 IB14 Osteosarcoma 16 Male Tel. PIA Poor Poor Lung
L1385 IB16 Osteosarcoma 13 Female Tel. MA Poor Poor Lung
L1016 IB19 Osteosarcoma 4 Male HG Conv. AP Poor Good 0
L2620 IB21 Osteosarcoma 16 Male HG Conv. AP Poor Poor Lung+bone
L1375 IB22 Osteosarcoma 8 Male HG Conv. AP Poor Good Local
L428 IB32 Osteosarcoma 16 Male HG Conv. AP Poor Good Lung
L436 IB33 Osteosarcoma 18 Male HG Conv. MA Poor Good 0
L432 IB34 Osteosarcoma 17 Male HG Conv. AP Poor Poor Lung
L361 IB35 Osteosarcoma 16 Female HG Conv. AP Poor Good 0
L1368 IB36 Osteosarcoma 10 Female HG Conv. PIA Good Good 0
L1376 IB37 Osteosarcoma 9 Female HG Conv. AP Good Good 0
L1386 IB38 Osteosarcoma 12 Female HG Conv. AP Poor Poor Lung
L2702 IB39 Osteosarcoma 16 Male HG Conv. AP Good Poor Lung
L2302 IB40 Osteosarcoma 19 Female HG Conv. AP Poor Good 0
L2296 IB41 Osteosarcoma 16 Male HG Conv. AP Good Poor Lung+else
L2295 IB42 Osteosarcoma 40 Female HG Conv. AP Poor Good 0
L2611 IB43 Osteosarcoma 20 Female HG Conv. AP Good Good 0
L2300 IB44 Osteosarcoma 13 Male HG Conv. AP Good Good 0
L2294 IB45 Osteosarcoma 17 Female HG Conv. AP Poor Good 0
L2290 IB46 Osteosarcoma 36 Male HG Conv. AP Poor Poor Local
L2301 IB47 Osteosarcoma 25 Male HG Conv. AP Poor Poor Lung+else
L2281 IB48 Osteosarcoma 17 Male HG Conv. AP Poor Poor Lung
L2289 IB54 Osteosarcoma 11 Male HG Conv. AP Poor Good 0
L578 IB55 Osteoblastoma 22 Male Relapse
L579 IB56
a Osteoblastoma 22 Male Relapse
L580 IB57 Osteoblastoma 13 Male Remission
L581 IB58 Osteoblastoma 16 Male Remission
L601 IB59 Osteoblastoma 44 Male Remission
FMSC-OB-diff IB49 Osteoblasts
MSC1-OB-diff IB50 Osteoblasts
220-OB-diff IB51 Osteoblasts
240-OB-diff IB52 Osteoblasts
MSC2-OB-diff IB53 Osteoblasts
MSC1 IB54 MSC
MSC2 IB61 MSC
C220R IB62 MSC
C240R IB63 MSC
FMSC IB64 MSC
Abbreviations: Adj. CT¼adjuvant chemotherapy; AP¼adriamycin and cisplatinum; HG¼high grade; HG conv¼high grade conventional; MA¼methotrexate and adriamycin;
MSC¼mesenchymal stem cell; OB¼osteoblastomas; PIA¼cisplatinum, ifosfamide and adriamycin; Tel.¼Telangiectatic.
aIB 56 is the recurrence from IB 55.
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swith non-necrotic tissue were used in this study. For osteoblas-
toma, resected tumours were used for RNA extraction.
We used human bone-marrow-derived mesenchymal stem cells
and osteoblasts derived from the same cells on osteogenic
differentiation. Cells were isolated from bone marrow samples as
previously described (Bernardo et al, 2007b). MSC1, MSC2 and
FMSC1 were obtained from the Department of Hematology, Leiden
University Medical Center, Leiden, The Netherlands. 220L and
240R were purchased from Tulane University, New Orleans,
LA, USA. All cells used were derived from adult patients, except
for FMSC1, which was derived from foetal bone marrow, and
were obtained according to the ethical guidelines of the natio-
nal organisation of scientific societies (FEDERA). All cells were
characterised either at passage 2 or passage 3 through FACS
analysis as previously described (Bernardo et al, 2007a).
The phenotypes were uniform among all the different cells tested
and in agreement with those reported for MSCs, that is, CD90,
CD105, CD166, HLA-A, B and C positive (495%), and CD34, CD
45, CD31, CD80 and HLA-DR negative (o5%). Furthermore, all
cells were tested for their ability to be committed under proper
conditions towards adipogenesis, chondrogenesis and osteogen-
esis, as previously described (Bernardo et al, 2007a). All cells that
were induced to osteogenic differentiation showed a diffused
positive staining for alkaline phosphatase activity and alizarin red
positive calcium depositions, as previously described (Bernardo
et al, 2007a).
All tissue samples were handled in a coded manner, according to
the National Ethical Guidelines (‘Code for Proper Secondary Use of
Human Tissue in The Netherlands’, Dutch Federation of Medical
Scientific Societies, http://www.federa.org).
Expression array analysis
Ribonucleic acid was extracted from frozen tissue sections of
20mm as described previously (Baelde et al, 2001). Generation of
cRNA and labelling were performed according to the Affymetrix
protocol. Briefly, 10mg of RNA was used to generate double-
stranded cDNA by an oligo-dT primer and a T7-RNA polymerase
promotor. Reverse transcription and subsequent amplification and
labelling were carried out in accordance with protocols recom-
mended by Affymetrix using the BioArray HighYield RNA
Transcript Labeling kit (ENZO Life Sciences, Farmingdale, NY,
USA). Every step of the reverse transcription and labelling
procedure is monitored by gel electrophoresis and spectro-
photometry.
Labelled RNA is hybridised with Hu133A GeneChip Arrays
(Affymetrix, Santa Clara, CA, USA) according to the manufac-
turer’s protocol (http://www.affymetrix.com/support/technical/
manuals.affx) and scanned on an Affymetrix GeneChip scanner.
The quality of hybridisation is assessed by calculating the ratio
of 50 and 30 features for the reference genes, GAPDH and actin.
When this ratio is greater than 2, it indicates a measure of poor
quality and the chip is discarded.
All expression array data are available at the BJC online
supplementary material website.
Data analysis
GeneChip data were normalised using GC-RMA, an algorithm
provided by the Bioconductor project (http://www.bioconductor.
org/), which considers only perfect match values (Gautier et al,
2004). The algorithm runs under statistical language R and was
shown to give less false-positive variance in technical duplicates
and has a greater sensitivity and specificity (Irizarry et al, 2003), as
was recently confirmed in our laboratory (Sieben et al, 2005).
The Spotfire decision site for functional genomics was used to
perform unsupervised hierarchical clustering on all genes with a
variance of at least 0.5.
To select genes that can be used as classifiers for histological
response on preoperative treatment and survival, the Limma
(linear models for microarray data) package of Bioconductor
(http://www.bioconductor.org) was applied to the data set. Limma
is a moderated T-statistic that detects differentially expressed
genes between groups, given the natural variance within these
groups, corrected for the false discovery rate due to multiple
testing (Wettenhall and Smyth, 2004).
For pathway analysis, array data were mined with GO-Elite, a
tool to identify pathways that are most significantly changed
between groups (http://www.genmapp.org/go_elite/go_elite.html
and PMID: 15961447). To visualise gene expression data in
biological pathways, GenMAPP was used (Dahlquist et al, 2002).
Quantitative reverse transcriptase PCR was performed as
described previously (Rozeman et al, 2005). Primers for control
genes and WNT5A have been submitted to the Real Time PCR
Primer and Probe Database (http://medgen.ugent.be/rtprimerdb/).
RESULTS
Comparing expression profiles of osteosarcomas
For 25 pre-operative biopsies from high-grade central osteosarco-
mas, we obtained good-quality genome-wide expression data. One
sample was repeated twice and three were repeated once to test for
technical reproducibility. All four samples were most similar to
their duplicates as demonstrated by hierarchical clustering, as
replicates always clustered together (data not shown). For further
analyses, we used only one of the replicates. The entire file
containing all expression profiling data can be found in
supplementary Table 1.
Hierarchical clustering of all osteosarcoma profiles did not
result in separation into groups, implying no big differences
between possible clinical subsets. Previous publications reported
that there are significantly differentially expressed genes when
comparing osteosarcomas from patients with good vs poor
response to chemotherapy (Man et al, 2005; Mintz et al, 2005).
However, we could not identify any significantly expressed gene
when comparing good and poor responders when applying a
moderated T-statistic that corrects for multiple testing as
described in the methods section.
For all patients, at least 5 years of follow-up data were available.
Poor survivors are defined as those having less than a 5-year
survival period compared with good survivors with more than a
5-year survival period. The same T-statistic was used for the
classification in good and poor survival; however, no significantly
differentially expressed genes were acknowledged and thereby no
prognostic markers were identified.
Genes differentially expressed based on comparison of
cultured cells and primary tissue
To identify the biological processes involved in osteosarcoma
genesis, the expression profiles of the 25 osteosarcomas were
compared with profiles of the presumed progenitors of this
tumour, that is, bone marrow-derived MSCs (n¼5) and osteo-
blasts derived from these MSCs (Bernardo et al, 2007b).
Furthermore, profiles of five osteoblastomas were included that
are not considered as benign precursors, as these tumours were
never reported to progress to osteosarcoma. Hierarchical cluster-
ing clearly distinguished the four groups into separate clusters
(Figure 1). The t-test in Limma assigned many significantly
differentially expressed genes when carrying out pair-wise
comparisons (Table 2).
The GO-Elite programme selected pathways that are most
significantly different when comparing groups, namely, GO-Elite
ranks pathways with excess of differentially expressed genes.
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sOne of the most significant pathways when comparing MSCs with
osteosarcoma was the MHC class II receptor activity pathway,
which was upregulated in osteosarcoma. It is difficult to under-
stand how the increase in such a pathway could contribute to
mesenchymal transformation. We hypothesised that some of the
genes identified by the t-test are merely different because cultured
cells (MSCs) are compared with primary tissue. The genes that are
most likely to belong to this category are those that show a similar
expression in cultured MSCs and osteoblasts, as well as in primary
osteosarcoma and osteoblastoma, but significant differences
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Figure 1 Hierarchical clustering. Hierarchical clustering of expression profiling data clearly shows separate clusters for osteosarcomas, osteoblastomas,
mesenchymal stem cells (MSCs) and the same MSCs differentiated into osteoblasts.
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sbetween the group of cultured cells and primary tissues. To
identify these genes, Venn diagrams were made of all differentially
expressed genes for all comparisons using the Limma package
from Bioconductor (http://www.bioconductor.org). A final Venn
diagram (Figure 2) identified 492 genes that are likely to be
different because of the comparison of cultured cells with primary
tissue. The overlapping category in Figure 2 consists of all genes
that are significantly different when cultured cells are compared
with tissue, for both the highly malignant osteosarcomas and the
benign osteoblastomas. The procedure to construct VENN
diagrams is explained in the legend of Figure 2. GennMAPP
analysis was performed on the entire data set, with the ‘culture-
tissue’ category being marked as the leading parameter in the
expression data set marked purple. The group of eight genes in the
MHC class II receptor pathway that had a P-value of o0.05 seems
to consist of seven genes that were assigned to the purple-coloured
‘culture-tissue’ category (Figure 3). This suggests that the approach
to filter out genes that may be the result of comparing cultured
cells and tissue is a valid one. However, this approach has its
limitations because separate genes cannot be validated with a gold
standard, nor can they be excluded, as there are genes in this set
that are similarly differentially expressed between MSCs in vivo vs
both osteoblastomas and osteosarcomas.
Comparing osteosarcoma with its presumed progenitors
The 25 osteosarcomas as a single group compared with five
cultures of undifferentiated mesenchymal stem cells. This resulted
in a substantial number of 2973 differentially expressed genes
(corrected P-valueo0.05), of which 1159 genes are higher
expressed in MSCs than in osteosarcomas and 1814 lower. We
further compared osteosarcomas with the same MSC cultures
Table 2 Group comparisons and number of significant genes identified with Benjamini–Hochberg adjusted P-value
Comparison Total Po0.05 Up Down Avg of 100 5 OS Presumed process
OS vs MSC 2973 1159 1814 2456 Genes that are altered in osteosarcoma (OS) progression from MSC
OS vs DO 3041 1144 1897 2586 Genes that are altered in OS progression from differentiated osteoblasts (DO)
OS vs OB 882 225 657 937 Genes involved in malignancy of OS compared with benign osteoblastoma (OB)
DO vs MSC 369 175 194 Genes involved in MSC differentiation to osteoblasts
OB vs MSC 1245 606 639 Genes involved in osteoblastoma progression from MSC
OB vs DO 1573 770 803 Genes involved in osteoblastoma progression from osteoblasts
OS-MS OB-MS
318
927
435
492
609
OSMS_OBMS OSDO_OBDO
1101
1940 472
OS-DO OB-DO
2046
Figure 2 Venn diagram of the ‘culture-tissue’ gene subset. The circles
from these VENN diagrams represent the differentially expressed genes
when comparing two groups of arrays. The overlap between two circles
contains genes that are the same in both comparisons.
OS¼osteosarcomas; OB¼osteoblastomas; MS¼mesenchymal stem
cells; DO¼MSCs differentiated into osteoblasts. The lower VENN
diagram shows the overlap of the 492 differentially expressed genes when
comparing expression profiles from primary tissue (OS, osteosarcoma and
OB, osteoblastoma) with those from cultured cells (MS MSCs and DO,
differentiated into osteoblasts). The circle OSMS_OBMS contains all genes
differentially expressed when comparing osteosarcoma and MSCs that
overlap with the differentially expressed genes when comparing osteo-
blastoma and MSC. OSDO_DOOB is the same as OSMS_OBMS, but for
MSCs differentiated into osteoblasts.
MHC class II receptor activity
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MHC class II receptor activity
Figure 3 MHC class II normal vs tissue culture related. The MHC class II
receptor activity pathway with genes that are differentially expressed
between osteosarcoma and mesenchymal stem cells (MSCs) coloured.
Green is upregulated in osteosarcoma, purple indicates that a gene belongs
to the 492 genes of the culture-tissue set. The left panel was analysed
without taking this set into account, the right set with the ‘culture-tissue’
gene set as the first parameter. The color reproduction of this figure is
available on the html full test version of the manuscript.
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sdifferentiated into osteoblasts. This resulted in 3041 differentially
expressed genes (Po0.05). Table 2 summarises the results of all
comparisons made. There is a large overlap of 1725 genes in
osteosarcomas vs MSCs and osteosarcomas vs differentiated
osteoblasts (DO). One gene that was significantly less expressed
in osteosarcoma was WNT5A. This gene, involved in non-b-
catenin Wnt signalling (Kuhl et al, 2000), has been tested with
quantitative RT–PCR on the same series of RNA that has been
used on microarrays as an alternative method to verify array data.
The correlation between qPCR and array data was good, that is,
92% (Figure 4).
Given the high number of significantly differentially expressed
genes, we did not consider it relevant to make a shortlist of the
most significant genes. Instead, the programme, GO-Elite, was
used to identify pathways with a high number of differentially
expressed genes and GENMAPP was used to specifically consider
pathways that are known to be involved in normal osteoblast
differentiation. For GO-Elite analysis, we removed the 492 ‘culture-
tissue’ artefact genes from the significant list.
Table 3 lists pathways that contain most differentially expressed
genes when comparing MSCs and osteosarcoma. Pathways in this
table have an adjusted P-value smaller than 0.05 upon strict
statistical criteria, that is, those by Benjamini and Hochberg
(1995). The significant pathways are associated with DNA
replication and mitosis, of which several genes involved in positive
regulation are upregulated in osteosarcoma, such as CCNB when
compared with MSC. None of the significant genes in these
pathways are identified as ‘culture-tissue artefacts’.
To further mine data, we considered specific pathways that are
known or suspected to be involved in osteosarcoma genesis.
Inactivation of the p53 pathway has been reported in osteosarcoma
(Wunder et al, 2005) and this is indeed confirmed when
comparing expression profiles from osteosarcoma with its
presumed progenitor, MSCs and osteoblasts. Figure 5 shows the
p53-mediated apoptotic pathway with genes that are down-
regulated in osteosarcoma (Po0.05) in green. Downregulation of
p53-mediated signalling is reflected by downregulation of the
specific downstream gene, BBC3/PUMA.
The Wnt pathway has been shown to have an important role in
osteoblast differentiation (Hartmann, 2006) and therefore, in this
study, we visualised this pathway with GenMAPP application using
expression data. Wnt signalling seems downregulated when
comparing MSCs or differentiated osteoblasts with osteosarcomas.
Figure 6 shows the Wnt pathway when comparing osteosarcomas
and MSCs. The picture is similar when comparing with osteoblasts,
although less prominent. Both upstream, the Wnt receptors FZD2
and -7 and LRP5 as downstream CCND1 and AXIN are down-
regulated.
Osteosarcoma vs osteoblastoma
Expression profiles of osteosarcoma were compared with those of
five osteoblastomas, a benign bone tumour occurring at a similar
site in long bones and in a similar age group as osteosarcoma.
The large difference in disease course is reflected by a large
set of significantly differentially expressed genes (n¼882), of
which 657 are higher in osteoblastoma and 225 are higher in
osteosarcoma. Comparing osteoblastomas with MSCs/osteoblasts
results in less differences (6%/7%) than with osteosarcomas
(13%). This may imply that osteoblastomas are more similar to
MSCs and osteoblasts than are osteosarcomas, thereby reflecting
the difference in malignancy. The pathways that are most
significantly altered when comparing osteosarcoma with osteo-
blastoma are the cell cycle, with an upregulation in malignant
tumours, and pathways associated with cell division, especially
regulation of the mitotic spindle. The significant pathways are
listed in Table 3. To determine whether the larger size of the
osteosarcoma group (n¼25) underlies this difference in signifi-
cant genes, we repeated the comparisons with only five
osteosarcomas. Calculations were repeated 100 times for different
combinations of 5 osteosarcomas and the results were averaged.
The results are shown in Table 2, in the column labelled ‘avg of
100 5 OS’. This indeed resulted in a reduction in the number of
12
10
8
6
4
2
0
0 0.5 1 1.5 2 2.5 3 3.5
Normalized q-RT PCR values
E
x
p
r
e
s
s
i
o
n
 
m
i
c
r
o
a
r
r
a
y
 
v
a
l
u
e
s
WNT5A
Figure 4 Quantitative RT-PCR for WNT5A. Comparison of q-RT-PCR
with array data for WNT5A shows 92% correlation.
Table 3 Differentially expressed significant pathways
Pathway Z-score
Comparison OS vs MSC
Macromolecule localization 5.99
Mitotic cell cycle checkpoint 5.00
DNA replication 4.57
Condensed chromosome, centromeric region 4.04
Comparison OS vs DO
Negative regulation of S phase of mitotic cell cycle 5.34
Comparison OS vs OB
Cell cycle 7.09
Spindle 6.34
IgG binding 5.69
Cell division 5.43
Condensed chromosome, centromeric region 5.36
Proteinaceous extracellular matrix 5.08
Chromosome segregation 4.94
DNA replication 4.80
Comparison DO vs MSC
Cadmium ion binding 11.28
Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity 7.39
Acute-phase response 5.57
Steroid biosynthetic process 5.14
Sterol metabolic process 5.12
Copper ion binding 4.45
Adipogenesis 4.67
Comparison OB vs MSC
Developmental process 7.53
Cholesterol biosynthesis 7.36
Proteinaceous extracellular matrix 5.27
Cytokine and chemokine mediated signaling pathway 4.48
Comparison DO vs OB
Negative regulation of transcription, DNA-dependent 5.58
Amine oxidase activity 4.99
Urogenital system development 4.94
Abbreviations: DO¼differentiated osteoblasts; MSC¼mesenchymal stem cell;
OB¼osteoblastoma; OS¼osteosarcoma; Z-score¼corrected score as determined
by GO-elite.
Osteosarcoma and its progenitors
A-M Cleton-Jansen et al
1914
British Journal of Cancer (2009) 101(11), 1909–1918 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
ssignificant genes, but the difference between osteosarcomas
and MSCs or osteoblasts was still substantial, that is, 11% for
MSCs and osteoblasts, whereas the comparison for osteoblastoma
was only 6 or 7%.
DISCUSSION
Previous studies on genome-wide expression profiling of osteo-
sarcoma have reported lists of genes that were found to be
differentially expressed when comparing tumours with a poor
histological response to chemotherapy and those with a good
response (Ochi et al, 2004; Man et al, 2005; Mintz et al, 2005). Our
study, comparing prechemotherapy biopsies from 8 good respon-
ders with those of 17 poor-responding patients did not result
in a single significantly differentially expressed gene. Size and
homogeneity of the patient cohort, type of expression profiling
platform and statistical analysis may all account for this lack of
significant genes. However, patient cohorts did not differ a
lot in size, that is, 30, 28 and 13 cases, respectively, compared
with 25 in our study, hence size seems to be a highly unlikely
explanation for this difference. A long follow-up was available for
our patient cohort for comparing the outcome of disease; however,
this did not result in the identification of significantly differentially
expressed genes.
Several meta-analysis studies on gene expression profiling
provide a clarification for the lack of consistent results between
different studies (Ein-Dor et al, 2005, 2006). reporting that there
are many genes associated with different clinical behaviour, but the
differences in expression are quite small and vary with different
patient cohorts. They conclude that a significant set of genes for
predicting survival requires thousands of patient samples. For a
relatively rare tumour-like osteosarcoma, this is obviously not
achievable, especially given the variation in clinical presentation
and treatment of this tumour.
To identify the possible biological characteristics of osteosarcoma,
a comparison of osteosarcoma expression profiles with profiles from
their presumed progenitors, that is, MSCs and osteoblasts derived
from these MSCs by in vitro differentiation, resulted in a large set of
2973 differentially expressed genes. This result validates our
statistical analysis, thereby justifying the negative results obtained
with the comparison within the osteosarcoma profiles. However, this
set of genes is definitely contaminated with a subset that is the result
of the different sources of primary tumour tissues and the in vitro-
cultured MSCs and osteoblasts. Identification of common differen-
tially expressed genes in osteosarcoma and benign osteoblastoma
(most probably derived from the same progenitor cells, but with a
completely different clinical behaviour) as compared with cultured
MSCs and osteoblasts identified pathways that could most probably
be attributed to the different sources of RNA. A subset of the 492
genes identified as commonly different in osteoblastoma and
osteosarcoma when compared with cultured MSCs and osteoblasts
could be assigned to specific pathways, thereby marking these as
possible ‘culture-tissue artefacts’. Especially the most significant
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spathway identified by GenMAPP analysis, that is, upregulation of the
MHC class II pathway in both osteosarcoma and osteoblastoma is
the most obvious example, most probably caused by infiltrating cells
that contaminate the tumour tissue, as has been described (Trieb
et al, 1998).
Pathways characterised by an excess of differentially expressed
genes between MSCs and osteosarcomas, but lacking the possible
‘culture-tissue artefacts’, are most likely involved in malignant
transformation. The GO-Elite application (http://www.genmapp.
org/go_elite/go_elite.html) generates a non-redundant list of
significant signal transduction pathways from the Gene Ontology
(GO) project from a gene list with specific criteria. The criteria in
this study included genes with a significant difference in mRNA
expression between osteosarcomas and MSCs or MSCs differen-
tiated to osteoblasts. Criteria were strict and corrected for false
discovery rate (FDR) due to multiple testing. On these restricted
P-values, the GO-Elite algorithm imposes another FDR correction.
Table 3 lists the pathways that survive this double FDR.
Pathways that subsist the FDR correction are involved in cell
cycle regulation, mitosis and DNA replication, the usual suspects
when comparing tumours with their progenitor cells. Osteosarco-
ma is especially characterised by a high growth rate and numerous
mitotic figures (Kilpatrick and Renner, 2003) and chemotherapy
protocols are aimed at inhibiting the cell cycle. However, the
current protocols are not effective in 40% of cases (Lewis et al,
2007a) and this may be because of a variable expression of certain
cell cycle components.
Of special interest are developmental pathways that are known
or suspected to have a role in osteosarcomagenesis. The Wnt
signalling pathway shows downregulation when comparing MSCs
or osteoblasts with osteosarcoma. Given the crucial role of this
pathway in normal osteogenesis (Hartmann, 2006) and tumour-
igenesis in general, this observation suggests a role for Wnt
signalling that differs from that in colorectal cancer, in which
upregulation of the pathway is considered to be crucial for
tumourigenesis (Klaus and Birchmeier, 2008). Indeed, we have
recently shown with a functional reporter assay that Wnt/b-catenin
signalling seems to be absent in osteosarcoma cell lines (Cai et al,
2009). In addition, we showed an absence of nuclear b-catenin
staining in primary osteosarcomas, indicative of inactive Wnt/
b-catenin signalling. Moreover, osteoblastomas showed a decrease
in genes involved in Wnt/b-catenin signalling. The noncanonical
WNT5A ligand, which is involved in Wnt/planar cell polarity (Qian
et al, 2007), however, was not changed. Both observations in
osteosarcoma and osteoblastoma can be clarified from the fact that
Wnt/b-catenin signalling is important for maintaining cells in the
MSC state (Baksh et al, 2007). Non-canonical Wnt signalling
mediated by WNT5A antagonises this activity and promotes
osteoblastogenesis of MSCs (Boland et al, 2004). Thus, loss of
WNT5A expression may be a key event in malignant transforma-
tion in osteosarcoma. The findings of this study have led us to
propose a model for osteosarcomagenesis, which is shown in
Figure 7. An increase in Wnt signalling when comparing DO with
MSCs is not observed. Wnt signalling changes during the process
of differentiation and at different phases in osteoblastogenesis,
whereby different Wnt activities are observed.
The comparison between osteoblastoma and the same
presumed progenitor cells, MSCs and osteoblasts, did not result
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sin pathways associated with cell cycle regulation. The profiles of
osteoblastomas have fulfilled a dual purpose in this study: they
were instrumental in identifying differentially expressed genes that
resulted from a difference in cell culture and primary tissue, and
they helped to recognise the cell cycle pathway as being most
important for malignant transformation of osteosarcoma.
From this analysis it can be concluded that osteosarcoma differs
from its presumed progenitor cells, MSCs and osteoblasts, in terms of
cell cycle regulation and developmental pathways. Benign osteoblas-
tomas with the same progenitor cells, but a much more favourable
disease course, are not characterised by an increase in cell cycle but
by a decrease in components of canonical Wnt signalling.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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